Charles River Laboratories International, Inc. (CRL) is a publicly traded Healthcare sector company. As of July 13, 2026, CRL trades at $231.04 with a market cap of $11.24B and a P/E ratio of -62.11. CRL moved -1.30% today. Year to date, CRL is +15.56%; over the trailing twelve months it is +42.62%. Its 52-week range spans $91.86 to $237.86. Analyst consensus is strong buy with an average price target of $220.36. Rallies surfaces CRL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CRL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $231.04 |
| Market Cap | $11.24B |
| P/E Ratio | -62.11 |
| EPS | $-3.70 |
| Dividend Yield | 0.00% |
| 52-Week High | $237.86 |
| 52-Week Low | $91.86 |
| Volume | 56.91K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.03B |
| Net Income | $-182.84M |
| Gross Margin | 0.00% |
13 analysts cover CRL: 0 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $220.36.